期刊
CLINICAL INFECTIOUS DISEASES
卷 75, 期 2, 页码 334-337出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciab1026
关键词
small molecule kinase inhibitors; ibrutinib; invasive fungal infections; cancer; opportunistic infections
We examined the incidence of invasive fungal infections (IFIs) within the first year of small molecule kinase inhibitor (SMKI) therapy based on administrative data analysis. The occurrence of IFIs ranged from 0.0% to 10.6% depending on the specific SMKI used, with midostaurin showing the highest incidence. Among the 1286 patients treated with ibrutinib, 38 individuals (3.0%) developed IFIs.
We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据